News | December 07, 2025
Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Subscribe To Our Newsletter & Stay Updated
